Your browser doesn't support javascript.
loading
Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.
Törlén, Johan; Ringdén, Olle; Le Rademacher, Jennifer; Batiwalla, Minoo; Chen, Junfang; Erkers, Tom; Ho, Vincent; Kebriaei, Partow; Keever-Taylor, Carolyn; Kindwall-Keller, Tamila; Lazarus, Hillard M; Laughlin, Mary J; Lill, Michael; O'Brien, Tracey; Perales, Miguel-Angel; Rocha, Vanderson; Savani, Bipin N; Szwajcer, David; Valcarcel, David; Eapen, Mary.
Affiliation
  • Törlén J; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Ringdén O; Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden; Division of Therapeutic Immunology, Karolinska Institutet, Stockholm, Sweden.
  • Le Rademacher J; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Batiwalla M; Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • Chen J; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Erkers T; Division of Therapeutic Immunology, Karolinska Institutet, Stockholm, Sweden.
  • Ho V; Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Kebriaei P; Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, Texas.
  • Keever-Taylor C; Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Kindwall-Keller T; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.
  • Lazarus HM; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.
  • Laughlin MJ; Stem Cell Therapeutics Program, Novartis Pharmaceuticals Inc, East Hanover, New Jersey.
  • Lill M; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
  • O'Brien T; Centre for Children's Cancer & Blood Disorders, Sydney Children's Hospital, Sydney, NSW, Australia.
  • Perales MA; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rocha V; Department of Clinical Haematology, Churchill Hospital, Oxford University Hospital, Oxford, United Kingdom.
  • Savani BN; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Szwajcer D; Department of Hematology, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Valcarcel D; Department of Hematology, Hospital Vall d'Hebron, Barcelona, Spain.
  • Eapen M; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: meapen@mcw.edu.
Biol Blood Marrow Transplant ; 20(9): 1418-25, 2014 Sep.
Article in En | MEDLINE | ID: mdl-24892261
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transplantation, Homologous / Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / Antigens, CD34 / Transplantation Conditioning Type of study: Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2014 Type: Article Affiliation country: Sweden
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transplantation, Homologous / Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Hematopoietic Stem Cell Transplantation / Antigens, CD34 / Transplantation Conditioning Type of study: Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2014 Type: Article Affiliation country: Sweden